City of Hope, an innovative biomedical research, treatment and educational institution with over 6,000 employees, is dedicated to the prevention and cure of cancer and other life-threatening diseases and guided by a compassionate, patient-centered philosophy.
Founded in 1913 and headquartered in Duarte, California, City of Hope is a remarkable non-profit institution, where compassion and advanced care go hand-in-hand with excellence in clinical and scientific research. City of Hope is a National Cancer Institute designated Comprehensive Cancer Center and a founding member of the National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers that develops and institutes standards of care for cancer treatment.
This position is in Dr. Helena Reijonen’s https://www.cityofhope.org/helena-reijonen laboratory at the Department of Diabetes Immunology within the Diabetes & Metabolism Research Institute at the City of Hope, https://www.cityofhope.org/research/diabetes-metabolism-research-institute. The main focus of Dr Reijonen’s research is the understanding of the cause of type 1 diabetes and translating this knowledge into immune therapies with the ultimate goal to cure the disease.
Key Responsibilities include:
Gained knowledge of the genetic and mechanistic pathways leading to the destruction of the insulin producing beta cells by the individual’s own immune system will be translated into targeted intervention strategies to stop this process and protect beta-cells. We also aim at the discovery of immune correlates that can predict progression of type 1 diabetes before the clinical symptoms of the disease appear. These immune correlates are also valuable for the monitoring of the outcomes of islet transplantation in type 1 diabetes patients and in the evaluation of efficacy of the targeted therapies in diverse patient populations.